Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JNJ

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.

Benzinga

Johnson & Johnson Stock: Is Wall Street Bullish or Bearish?

Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.

Barchart

Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations

Patience and a tolerance for risk may be necessary, but these Hold stocks could eventually see big gains, according to analysts.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson Johnson (NYSE:JNJ) and Kenvue Inc (NYSE:KVUE), accusing the companies of misleading pregnant women about the safety of Tylenol despite evidence suggesting its active ingredient, acetaminophen, may increase the risk of autism and attention disorders in children.

Benzinga

Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy

On Thursday, Johnson Johnson (NYSE:JNJ) announced positive topline results from a recent study.

Benzinga

Johnson & Johnson, Kenvue Named In First Ever UK Legal Action Over Talc Cancer Claims

Thousands of claimants in the U.K. are suing Johnson Johnson (NYSE:JNJ), accusing the healthcare giant of knowingly selling asbestos-contaminated talcum powder that allegedly caused cancer in consumers. The case, involving roughly 3,000 individuals, is one of the largest product liability claims of its kind to reach the High Court in…

Benzinga

Johnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks

A legal claim involving 3,000 people has been reportedly filed against Johnson Johnson (NYSE:JNJ) in the U.K., alleging that the company knowingly sold asbestos-contaminated baby powder.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

On Tuesday, Johnson Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

Benzinga

Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off

Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock.

MarketBeat

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Health care giant Johnson Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.

Benzinga

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

The Food and Drug Administration (FDA) has updated safety labeling for Johnson Johnson's (NYSE:JNJ) Carvykti after receiving reports of immune effector cell-associated enterocolitis (IEC-EC)—a rare but serious complication seen in both clinical trials and postmarketing data.

Benzinga

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

Barchart

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.

Benzinga

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

Barchart

What to Expect From Johnson & Johnson’s Q3 2025 Earnings Report

Johnson & Johnson is expected to release its fiscal third-quarter earnings next month, and analysts project a double-digit earnings rise.

Barchart

Why This Dividend King Still Stands Tall

With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.

Benzinga

Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors

Johnson Johnson (NYSE:JNJ) is reportedly halting international sales of its Linx Reflux Management System, a device used to treat chronic acid reflux.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism

CNBC’s Jim Cramer warned Tuesday that President Donald Trump is creating a “nightmare of potential litigation” for consumer health giant Kenvue Inc. (NYSE:KVUE), sending the company's stock tumbling.

Benzinga

Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients

Johnson Johnson (NYSE:JNJ) on Friday announced that an investigational immune-based induction regimen with Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).

Benzinga

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials

Johnson Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) on Wednesday released new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies of icotrokinra compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis.

MarketBeat

3 Dividend Stocks to Hold Through Market Volatility This Fall

Interest rate cuts may not decrease market volatility; discover three dividend stocks that can deliver stability, income, and growth during this fall

Benzinga

Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 Next

Despite ongoing legal battles related to its talc products, Johnson Johnson (NYSE:JNJ) stock has climbed over 23% year-to-date.

Benzinga

Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).

Benzinga

Johnson & Johnson Kicks Off 'Powerful New Product Cycle': Analyst

Johnson Johnson (NYSE:JNJ) on Tuesday won regulatory approval for its drug delivery product Inlexzo to treat high-risk non-muscle invasive bladder cancer, a milestone Goldman Sachs says could launch “a powerful new product cycle” for the company's TAR-200 program.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.